healthevidencedigest

Tag: PCOS

  • GLP-1 Medications and PCOS: What the 2026 Research Actually Shows About Fertility, Ovulation, and Pregnancy Safety

    GLP-1 Medications and PCOS: What the 2026 Research Actually Shows About Fertility, Ovulation, and Pregnancy Safety

    📌 What this article covers Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are being prescribed at rapidly increasing rates to women with PCOS, despite the fact that neither drug is FDA-approved for PCOS specifically. This article synthesizes what the peer-reviewed research as of 2026 shows about how GLP-1 medications affect ovulation, menstrual regularity, fertility, and pregnancy outcomes in women with PCOS. It also covers what current evidence does not show, because on this topic the gaps matter as much as the findings. This is not medical advice. If you have PCOS and are taking or considering a GLP-1 medication, the information here is a starting point for a conversation with your prescriber, not a substitute for one.

    Something has shifted in PCOS treatment over the past four years. GLP-1 receptor agonists, the class of medications that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), were originally developed for type 2 diabetes and then approved for chronic weight management. But prescribing data tells a different story about how they are actually being used. In women with PCOS, GLP-1 prescribing increased from roughly 2% of patients in 2021 to approximately 18% by 2025. That is nearly a tenfold increase, in a condition for which these drugs have no formal FDA approval.

    The clinical logic is not hard to follow. PCOS is tightly linked to insulin resistance and excess weight, and GLP-1 medications address both. Many women with PCOS report improvements in their symptoms after starting these drugs. Some report spontaneous conception after years of struggling with ovulatory dysfunction. The popular media has described this as “Ozempic babies,” and the coverage has ranged from enthusiastic to alarming.

    What does the peer-reviewed evidence actually show in 2026? The answer is more nuanced, and more honest about uncertainty, than most of what is circulating online.

    What PCOS Is and Why Metabolism Matters So Much

    Polycystic ovary syndrome affects an estimated 6 to 13% of reproductive-aged women worldwide, making it the most common endocrine disorder in this population. Despite its name, you do not need polycystic ovaries to have PCOS. The diagnosis is clinical, based on the Rotterdam criteria, which require at least two of three features: ovulatory dysfunction, clinical or biochemical signs of elevated androgens, and polycystic ovarian morphology on ultrasound.

    What defines PCOS at the metabolic level is a vicious cycle involving insulin resistance and androgen excess. Elevated insulin drives the ovaries to produce more androgens. Those androgens worsen insulin sensitivity. The resulting hyperinsulinemia suppresses sex hormone-binding globulin (SHBG), which increases free testosterone levels. The whole system feeds back on itself, and ovulation pays the price.

    Between 40 and 90% of women with PCOS are overweight or obese, and insulin resistance is present even in roughly 60% of lean women with PCOS. This metabolic backdrop is why treatments that improve insulin sensitivity, including metformin, lifestyle modification, and now GLP-1 medications, have attracted so much interest for their potential reproductive benefits. The metabolic and reproductive problems in PCOS are not separate issues. They are the same issue, viewed from different angles.

    If you are navigating a recent PCOS diagnosis, our resources page has links to clinical guidelines and patient advocacy organizations.

    How GLP-1 Medications Work, and Why They Might Help in PCOS

    GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals the pancreas to release insulin in a glucose-dependent way, suppresses glucagon, slows gastric emptying, and reduces appetite through direct action on the brain. GLP-1 receptor agonists are synthetic versions of this hormone, engineered to last longer in the body than the natural peptide, which degrades within minutes.

    The drugs most widely used in PCOS discussions are:

    • Semaglutide (weekly injection: Ozempic for diabetes, Wegovy for weight management; daily oral: Rybelsus)
    • Liraglutide (daily injection: Victoza for diabetes, Saxenda for weight management)
    • Tirzepatide (weekly injection: Mounjaro for diabetes, Zepbound for weight management), which targets both GLP-1 and GIP receptors

    The connection to PCOS is mechanistic. If GLP-1 medications reduce insulin resistance, lower circulating insulin, and promote weight loss, then the downstream hormonal environment in the ovary should improve. Reduced insulin means reduced ovarian androgen production. Reduced androgens mean higher SHBG, lower free testosterone, and potentially restored ovulatory function.

    Beyond the indirect metabolic pathway, there is some evidence that GLP-1 receptors are expressed directly in reproductive tissues, including the pituitary, ovaries, and endometrium. This has raised the question of whether GLP-1 medications might have direct effects on follicular development and ovulation, independent of weight loss. The honest answer from the current evidence is: possibly, but we cannot separate this cleanly from the effects of metabolic improvement in human studies.

    What the Research Shows: Ovulation and Menstrual Regularity

    The clinical evidence for GLP-1 medications improving ovulatory function in PCOS is real, but it comes from studies that are mostly small, short, and conducted in women who were also losing weight and improving insulin sensitivity simultaneously.

    A 2026 narrative review published in the Journal of Clinical Medicine by Abedi et al. synthesized 49 studies on GLP-1 receptor agonists and reproductive outcomes. The review found consistent signals across multiple study designs:

    • GLP-1 medications improve menstrual regularity and ovulatory frequency in women with obesity and PCOS
    • Several trials reported improvements in LH and progesterone profiles, reduced androgen levels, and increased SHBG
    • One randomized trial that compared exenatide to metformin in women with PCOS reported spontaneous pregnancy rates of 43.6% with exenatide versus 18.7% with metformin after 12 weeks

    That last number is striking enough to warrant a caveat. It comes from a single trial, in a selected population, with a 12-week window. It should not be extrapolated as a reliable estimate of what any given woman with PCOS can expect from a GLP-1 medication. What it tells us is that the fertility signal is real and worth taking seriously, not that the magnitude is established.

    The review authors concluded that GLP-1 medications may improve ovulatory function and menstrual regularity in women with obesity and PCOS, but were careful to note that most of the observed reproductive benefit likely reflects metabolic normalization rather than direct drug action on the ovary. That distinction matters clinically, because it suggests that sustained metabolic improvement, not just the drug itself, is probably what drives the reproductive benefit.

    A 2024 study published in Nature Communications by Sánchez-Garrido et al. tested GLP-1-based multi-agonist compounds, including a GLP-1/Estrogen conjugate and a GLP-1/GIP/Glucagon triple agonist, in two mouse models of PCOS. The GLP-1/Estrogen combination showed superior metabolic efficacy compared to any other multi-agonist or to metformin, and in one of the mouse models (the ovulatory PCOS model), also improved ovarian cyclicity without causing uterotrophic effects. This is preclinical research and cannot be directly applied to human treatment, but it provides mechanistic support for the idea that GLP-1-based combinations may have effects on PCOS-related ovarian dysfunction beyond what either component achieves alone. Next-generation multi-agonist compounds are likely to reach clinical trials in PCOS populations in the coming years.

    The RESTORE Trial: The Human Evidence We Have Been Waiting For

    The most important ongoing clinical trial in this space is RESTORE (NCT05662098), a randomized controlled trial actively enrolling women aged 12 to 35 with PCOS and obesity. RESTORE is directly testing whether semaglutide improves reproductive and metabolic outcomes in PCOS in a rigorous, prospective design. Primary endpoints include ovulatory frequency, hormonal parameters, and metabolic markers. The trial is expected to generate data that will meaningfully advance the field beyond the observational and small interventional studies that currently form the evidence base.

    Until RESTORE reports, the clinical case for GLP-1 medications in PCOS rests on mechanistic plausibility, indirect trial data, and a growing body of real-world experience. That is a reasonable basis for individualized clinical decision-making with an informed prescriber. It is not yet a basis for definitive guidelines.

    The Fertility Paradox: Restored Ovulation and Unintended Pregnancy

    Here is where the clinical picture becomes more complicated, and where the evidence carries a warning that is underrepresented in popular coverage.

    If GLP-1 medications restore ovulatory function in women with PCOS who previously had irregular or absent ovulation, those women become fertile in ways they may not have been before. If they are sexually active and not using reliable contraception, unintended pregnancy becomes a real possibility.

    The Abedi et al. review notes that this creates what they describe as a clinical paradox: the same drug that offers reproductive benefit can also increase the risk of conception at a time when the drug itself is still in the body, and when current guidance recommends discontinuing GLP-1 medications before pregnancy.

    This is not a theoretical concern. Prescribing data from Australia documented a rapid rise in GLP-1 prescribing in reproductive-aged women, with increasing overlap between GLP-1 initiation and contraceptive use patterns. Real-world data from across multiple countries show that inadvertent pregnancy exposure is becoming more common.

    A separate pharmacokinetic issue is relevant here specifically for semaglutide. Semaglutide has an elimination half-life of approximately one week, meaning the drug accumulates with weekly dosing and persists in the body for several weeks after the last dose. Current prescribing recommendations advise discontinuing semaglutide approximately two months before attempting conception to reduce drug exposure during early organogenesis, the critical developmental window of weeks three through eight of pregnancy, when organ formation occurs.

    For tirzepatide, there is an additional concern that is specific to this drug: clinical guidance indicates that tirzepatide may reduce oral contraceptive exposure during treatment initiation and dose escalation, which could compromise contraceptive effectiveness. Women starting tirzepatide who rely on oral contraceptives should discuss backup contraception options with their prescriber.

    The bottom line for women with PCOS who are on a GLP-1 medication and not trying to conceive: contraception planning needs to be part of this conversation. The Abedi et al. review found evidence that this counseling is not consistently being delivered in routine clinical practice.

    What the Evidence Shows About Pregnancy Safety

    This is the question most women want answered, and it is also the one where the evidence is most limited.

    What we know

    The available human data on GLP-1 medication exposure during pregnancy come from regulatory pharmacovigilance datasets, observational cohorts, national registries, and case reports. These are not randomized pregnancy trials, because those studies cannot ethically be conducted. The findings to date are cautiously reassuring but far too limited to be interpreted as evidence of safety.

    Key findings from the Abedi et al. review include:

    • An analysis of FDA and EMA regulatory data by Parker et al. identified 164 unplanned pregnancies among approximately 32,000 GLP-1-treated women. Outcomes included 43% live births, 22% spontaneous abortions, and 2.7% congenital anomalies, which were comparable to the placebo group in those datasets.
    • A Danish cohort study of more than 104,000 pregnancies, including 32 with first-trimester semaglutide exposure, found no increase in major malformations.
    • A Taiwanese cohort of women with pregestational type 2 diabetes found no increased risk of major congenital malformations after periconceptional GLP-1 exposure compared to insulin, though confounding by the underlying diagnosis remains a limitation.
    • The InPreSS consortium evaluated more than 50,000 pregnancies in women with pregestational type 2 diabetes and found no increased risk of major congenital malformations after periconceptional GLP-1 exposure compared to insulin.

    Collectively, these studies do not identify a consistent teratogenic signal. But the review authors are explicit that the absence of a clear teratogenic signal should not be interpreted as confirmation of safety. Sample sizes for the exposed groups are small. Confounding by the underlying conditions (diabetes, obesity) is difficult to fully adjust for. And early pregnancy losses may be incompletely captured.

    What the animal studies show

    Preclinical studies across rodent and rabbit models showed dose-dependent reductions in fetal weight, delayed bone formation, and skeletal variants when GLP-1 medications were administered during pregnancy. Mechanistic studies with semaglutide specifically showed reductions in fetal and placental growth and downregulated placental nutrient transport systems in late-gestation models.

    Importantly, many of these preclinical findings occurred alongside maternal weight loss and reduced food intake, making it difficult to attribute the fetal effects specifically to the drug rather than to nutritional restriction. This is an important interpretive nuance that is often missing from both alarming and reassuring headlines.

    One partial reassurance from the pharmacokinetic side: placental transfer studies of large peptide GLP-1 medications (specifically dulaglutide) found very low maternal-to-fetal transfer at term, approximately 0.2 to 0.7%, suggesting limited direct fetal exposure for some agents. But this does not eliminate concern, particularly early in pregnancy, and findings may differ across agents.

    What to Ask Your Doctor: A Practical Guide

    If you have PCOS and are currently taking or considering a GLP-1 medication, these are the questions worth bringing to your prescriber.

    If you are not trying to conceive:

    • Is my current contraceptive method reliable on this medication? (Relevant especially for oral contraceptives with tirzepatide)
    • Do I understand that improved ovulation may increase my fertility even if I have had irregular periods?
    • What is the plan if I become pregnant while on this medication?

    If you are planning to conceive in the next year:

    • How far in advance should I stop this medication before trying to conceive?
    • What metabolic management plan will replace the medication after I stop, to prevent rebound weight gain and worsening insulin resistance?
    • Are there clinical trials I would be eligible for, including RESTORE?

    If you have had an unintended pregnancy while on a GLP-1 medication:

    • The review by Abedi et al. recommends individualized assessment rather than reflexive reassurance or alarm. Multidisciplinary care involving endocrinology, obstetrics, and potentially maternal-fetal medicine is appropriate in this situation.

    What Still Needs to Be Answered

    The evidence gaps in this area are significant, and researchers are aware of them.

    The most important outstanding questions include:

    • Do GLP-1 medications have direct effects on follicular development and ovulation in women with PCOS, beyond what is explained by weight loss and improved insulin sensitivity?
    • What are the pregnancy outcomes specifically in women with PCOS (as opposed to women with type 2 diabetes) who are exposed to these drugs periconceptionally?
    • How should these medications be sequenced and discontinued in women planning pregnancy, particularly given the weight rebound that often follows discontinuation?
    • What are the reproductive safety profiles of tirzepatide and newer dual and triple agonists specifically, since most of the existing data focuses on semaglutide and liraglutide?

    Large prospective pregnancy registries with standardized definitions and outcomes are the path forward. The field needs them urgently, because real-world exposure is already far ahead of the evidence base.

    The Broader Context: GLP-1s and Women’s Health in 2026

    The rapid expansion of GLP-1 prescribing into PCOS and women’s reproductive health is part of a broader pattern of these medications crossing into conditions they were not originally developed for. That pattern is not inherently problematic. Metformin followed a similar path in PCOS, and the evidence eventually caught up. But the pace of prescribing in PCOS has outrun the evidence in ways that make careful clinical counseling essential.

    The evidence supports cautious optimism about GLP-1 medications for metabolic and reproductive improvement in women with PCOS. It also supports genuine uncertainty about pregnancy safety. Both of those things are true simultaneously, and patients deserve to understand both.

    For related coverage of how changing evidence is reshaping women’s health care, including the new 2026 cervical cancer screening guidelines that now allow self-collection for HPV testing, see our post here. For our earlier analysis of semaglutide in PCOS clinical trials, including a breakdown of the RESTORE trial design and what the research will need to show, see Ozempic for PCOS: Clinical Trials Are Testing It Right Now.

    Sources

    Primary narrative review: Abedi MM, Patni MM, Shajahan ANB, et al. GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review. Journal of Clinical Medicine. 2026;15(9):3204. doi:10.3390/jcm15093204

    Nature Communications multi-agonist study: Sánchez-Garrido MA, Serrano-López V, Ruiz-Pino F, et al. Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy. Nature Communications. 2024;15:8498. doi:10.1038/s41467-024-52898-y

    RESTORE trial registration: NCT05662098. ClinicalTrials.gov.

    InPreSS consortium: Cesta CE, Rotem R, Bateman BT, et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Internal Medicine. 2024;184:144-152. doi:10.1001/jamainternmed.2023.6663

    Danish semaglutide cohort: Kolding L, et al. Pregnancy outcomes after semaglutide exposure. Basic and Clinical Pharmacology and Toxicology. 2025;136:e70021.

    Parker regulatory analysis: Parker CH, Slattery C, Brennan DJ, le Roux CW. GLP-1 receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials. Diabetes, Obesity and Metabolism. 2025;27:4102-4108.

    PCOS overview: National Institute of Child Health and Human Development. Polycystic Ovary Syndrome.

    Disclaimer: Health Evidence Digest provides general information about clinical research and health topics for educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment. GLP-1 medications (semaglutide, tirzepatide, liraglutide) are not FDA-approved for PCOS. Treatment decisions, contraception planning, and preconception counseling should be made in consultation with a licensed healthcare provider who can evaluate your individual health history. If you are pregnant or planning pregnancy while taking a GLP-1 medication, contact your prescriber promptly.
  • Ozempic for PCOS? Clinical Trials Are Testing It Right Now. Here’s What the Research Will Need to Show.

    Ozempic for PCOS? Clinical Trials Are Testing It Right Now. Here’s What the Research Will Need to Show.

    If you have polycystic ovary syndrome and have been following health news over the past year or two, you have almost certainly wondered about semaglutide. The GLP-1 receptor agonist that transformed conversations about obesity and type 2 diabetes is now being formally investigated as a treatment for PCOS. Multiple clinical trials are actively enrolling patients in 2026.

    The scientific rationale is genuinely compelling. The existing evidence from smaller studies is encouraging. But there is an important distinction between buzz and evidence, and for a condition as complex and heterogeneous as PCOS, that distinction matters enormously. Semaglutide is not approved for PCOS. No drug is specifically approved for PCOS. The question these trials are trying to answer is whether semaglutide should be.

    This post covers the biology behind why semaglutide makes sense for PCOS, what published data already shows, which trials are now running and what they are specifically measuring, and what questions still need answers before this becomes standard practice.

    PCOS: Why Treatment Has Always Been a Patchwork

    Polycystic ovary syndrome affects an estimated 10% of women of reproductive age worldwide, making it one of the most common endocrine disorders in women. Despite that prevalence, there is no FDA-approved drug specifically for PCOS. Treatment today consists of medications developed for other conditions, repurposed off-label: oral contraceptives for cycle regulation, metformin for insulin resistance, spironolactone for androgen-related symptoms like excess hair growth and acne, and fertility medications for those trying to conceive.

    The patchwork approach exists because PCOS is not a single disease. It is a syndrome with multiple overlapping features that present differently from woman to woman. To receive a PCOS diagnosis under the Rotterdam criteria, a woman must have two of the following three: irregular or absent ovulation, elevated androgen levels (causing symptoms like hirsutism, acne, and hair loss), and polycystic-appearing ovaries on ultrasound. Many but not all women with PCOS also have insulin resistance and metabolic features. A significant proportion have obesity. A meaningful minority, sometimes estimated at 20 to 30%, are lean.

    What PCOS actually involves: the four main feature clusters Ovulatory dysfunction: Irregular or absent periods, anovulation, and associated difficulty conceiving. This is the most common reason women seek evaluation. Hyperandrogenism: Elevated testosterone and related androgens causing hirsutism (excess body and facial hair), acne, and androgenic hair loss. This is the feature most affecting quality of life for many women. Metabolic features: Insulin resistance (present in 50 to 70% of women with PCOS regardless of weight), dyslipidemia, elevated fasting glucose, and increased risk of type 2 diabetes and cardiovascular disease later in life. Psychological features: Depression, anxiety, and disordered eating occur at significantly higher rates in women with PCOS than in the general population, though these are often underaddressed in standard care.

    Why Semaglutide Makes Biological Sense for PCOS

    Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide 1, a gut hormone that stimulates insulin secretion in response to meals, slows gastric emptying, and signals satiety to the brain. It was developed for type 2 diabetes and obesity, both conditions strongly driven by insulin resistance. This is where the PCOS connection begins.

    In PCOS, insulin resistance is not just a complication. It is a central driver and amplifier of the disorder. Elevated insulin levels act directly on the ovary, specifically on theca cells, to stimulate androgen production. More insulin means more testosterone and DHEA-S. More androgens mean disrupted follicle development, impaired ovulation, and worsened symptoms. It also feeds back into insulin resistance through inflammatory and metabolic pathways, creating a self-reinforcing cycle.

    Reducing insulin resistance has long been a therapeutic target in PCOS. Metformin, the current first-line metabolic treatment, works primarily by reducing hepatic glucose output and improving insulin sensitivity. GLP-1 receptor agonists reduce insulin resistance through a complementary but distinct pathway: they enhance glucose-stimulated insulin secretion, reduce postprandial glucose spikes, lower fasting insulin, and produce significant weight loss that further improves insulin sensitivity. For many women with PCOS, this combination of effects addresses multiple features of the disorder simultaneously.

    For a broader overview of what the 2026 research shows about GLP-1 medications across the full spectrum of fertility, ovulation, and pregnancy safety in PCOS, see our companion post: GLP-1 Medications and PCOS: What the 2026 Research Actually Shows.

    What Published Evidence Already Shows

    The current evidence base for GLP-1 receptor agonists in PCOS comes from a mix of older liraglutide trials, smaller semaglutide studies, and published meta-analyses that synthesize this literature. It is encouraging. It is also preliminary.

    The published meta-analyses

    A 2024 meta-analysis published in the Journal of Diabetes and Its Complications pooled data from four randomized controlled trials involving 176 women with PCOS treated with GLP-1 receptor agonists (primarily liraglutide, with some semaglutide). Compared to placebo, GLP-1 agonists produced:

    OutcomeResult vs. placebo
    Waist circumferenceReduced by 5.16 cm (95% CI 4.21 to 6.11; p less than 0.00001)
    BMIReduced by 2.42 units (95% CI 1.74 to 3.10; p less than 0.00001)
    Serum triglyceridesReduced significantly (MD −0.20 mmol/L; p less than 0.00001)
    Total testosteroneReduced significantly (MD −1.33 nmol/L; 95% CI −2.55 to −0.12; p=0.03)
    HOMA-IR (insulin resistance)Significant improvement

    Source: Morais et al. Journal of Diabetes and Its Complications. 2024;38(10):108834. doi:10.1016/j.jdiacomp.2024.108834

    A May 2025 meta-analysis in Scientific Reports, searching databases through October 2024, reached broadly consistent conclusions: GLP-1 receptor agonists outperformed both placebo and metformin on anthropometric and metabolic outcomes in women with PCOS, with additional improvements in androgen markers and lipid profiles.

    The liraglutide RCT and the menstrual regularity finding

    The most robust individual trial in this space is the Nylander et al. 2017 randomized controlled trial published in Human Reproduction, which enrolled 72 women with PCOS. Participants received liraglutide (the predecessor GLP-1 agonist to semaglutide) for 26 weeks. Results showed significant reductions in BMI, free androgen index, fasting insulin, and LH/FSH ratio compared to placebo. Notably, 44% of women in the liraglutide group achieved regular menstrual cycles by week 24 versus significantly fewer in the placebo group. That menstrual regularity finding is the most clinically meaningful single result from the existing literature.

    Combination semaglutide plus metformin

    A prospective randomized controlled trial published in 2025 specifically examining overweight and obese women with PCOS assigned participants to metformin alone, semaglutide alone, or combination therapy. The combination group outperformed metformin monotherapy in reducing BMI, androgen levels, insulin resistance, and menstrual irregularities. Notably, the natural pregnancy rate was significantly higher in the combination group than in the metformin-only group. This is the most direct evidence to date supporting a fertility benefit, though the trial was not large enough to draw definitive conclusions and was conducted in a specific patient population.

    The honest limitations of the existing evidence base The published meta-analyses and most individual trials have important limitations that must be acknowledged before drawing clinical conclusions. Sample sizes are small: The 2024 meta-analysis pooled just 176 participants across four trials. The 2025 Scientific Reports meta-analysis similarly covered a limited participant pool. These are underpowered to detect meaningful differences in rarer outcomes like live birth rates. Populations are selective: Most trials enrolled women with PCOS and obesity or overweight. The evidence base for women with lean PCOS (BMI under 25 with documented insulin resistance) is far more limited, and some benefits may be primarily mediated through weight loss rather than any direct hormonal effect. Follow-up is short: Most trials run 12 to 28 weeks. The long-term effects of GLP-1 agonist use on reproductive function, ovarian reserve, and metabolic health in young women with PCOS over years of use are not yet characterized. Primary endpoints vary: Different trials measured different outcomes. Without a consistent primary endpoint across studies, synthesizing results into a definitive conclusion is difficult. The ongoing trials are attempting to address this.

    The 2025 to 2026 Trials: What They Are Specifically Studying

    Several clinical trials registered and recruiting in 2025 and 2026 are specifically investigating semaglutide in women with PCOS. Here are the most relevant currently active programs.

    RESTORE trial: NCT05819853 (University of Colorado)

    This is the most clinically ambitious of the currently active trials. RESTORE (Role of Semaglutide in Restoring Ovulation in Youth and Adults with Polycystic Ovary Syndrome) is a Phase 3 study enrolling 80 girls and women aged 12 to 35 years old with obesity and PCOS. Participants receive up to 10 months of semaglutide with dose escalation per manufacturer recommendations, with a maximum dose of 1.7 mg.

    FeatureDetails
    NCT numberNCT05819853
    PhasePhase 3
    SponsorUniversity of Colorado, Denver
    Age range12 to 35 years
    Estimated enrollment80 participants
    TreatmentSemaglutide (Wegovy/Ozempic) injectable, 10 months, dose escalation to max 1.7 mg
    Primary endpointChange in ovulation frequency before and after semaglutide
    Secondary endpointsChange in whole-body insulin sensitivity; change in ovarian morphology; androgen levels; metabolic markers
    Projected completionFebruary 2028
    StatusRecruiting

    The choice of ovulation frequency as the primary endpoint is significant. Rather than measuring weight loss or metabolic markers as primary outcomes, RESTORE is asking the most clinically meaningful question for a reproductive-age population: does semaglutide restore the normal ovulatory function that PCOS disrupts? The adolescent inclusion (ages 12 to 17) is also notable, as it addresses the understudied question of whether early metabolic intervention in young women with PCOS can improve reproductive outcomes before the condition becomes entrenched.

    Semaglutide and PCOS: Emerging Treatment Strategy (NCT06222437)

    Sponsored by Methodist Health System, this Phase 1 single-arm interventional study focuses specifically on ovulation and androgen outcomes. Its primary objective is to determine the effect of semaglutide on ovulation and menstrual regularity, and it also measures testosterone, sex hormone-binding globulin (SHBG), and changes in hirsutism. This is one of the few trials that lists androgen-specific clinical measures (not just lab values) as a primary focus, making it directly relevant for women whose main PCOS burden is hirsutism and acne rather than fertility concerns.

    Semaglutide vs. metformin in PCOS (NCT05646199, NCT06896981)

    Two Phase 2/3 trials are specifically comparing semaglutide against the current standard metabolic therapy for PCOS. The University of Hull trial (NCT05646199) randomizes 60 women with PCOS and obesity to semaglutide or metformin over 28 weeks, with primary endpoint of weight loss and secondary endpoints including free androgen index, glucose tolerance, and blood pressure. The Bangladesh trial (NCT06896981) is evaluating the combination of low-dose semaglutide plus metformin versus metformin alone over 12 weeks in 30 women with PCOS and obesity.

    The metformin comparison matters clinically. If semaglutide is going to displace or be added to metformin in PCOS care, it needs to demonstrate it does something meaningfully better than the existing cheap, well-tolerated, off-patent treatment. Head-to-head data is more actionable for prescribers than placebo-controlled data alone.

    What the Trials Will Need to Show

    For semaglutide to move from promising to proven in PCOS, the clinical trials will need to demonstrate several things that smaller studies have not yet conclusively shown.

    • Ovulatory restoration across the weight spectrum. Most trial participants have obesity. Whether semaglutide restores ovulation in normal-weight women with PCOS, where the mechanism is less clearly tied to weight loss and more to a possible direct hormonal effect, is not yet established.
    • Androgen normalization and symptom improvement. Lab values are useful, but what patients care about is whether hirsutism, acne, and hair loss actually improve. Trials need patient-reported outcome measures and validated clinical scales for these symptoms, not just serum testosterone numbers.
    • Live birth rates for women trying to conceive. This is the endpoint that matters most for a large proportion of the PCOS population. One trial showed higher natural pregnancy rates with combination semaglutide plus metformin, but live birth rate data is absent from most studies. And critically, semaglutide must be stopped before attempting conception, so the fertility benefit question is more nuanced than it first appears.
    • Long-term safety in reproductive-age women and adolescents. Semaglutide’s safety data comes predominantly from adults with diabetes or obesity, typically older than the PCOS population. The RESTORE trial’s inclusion of participants as young as 12 will generate important adolescent safety data that currently does not exist.
    • Efficacy in lean PCOS. Roughly 20 to 30% of women with PCOS have a BMI under 25. Their insulin resistance is real but may be less severe, and the weight loss mechanism that drives metabolic improvement in obese participants may contribute less to benefit in this group. None of the current trials are designed specifically for lean PCOS.

    The Pregnancy Contraindication: A Critical Practical Issue

    Semaglutide is contraindicated during pregnancy. This is not a precautionary label statement. Animal studies have shown fetal harm at doses producing exposures similar to the human therapeutic dose. The FDA prescribing information for both Ozempic and Wegovy includes a recommendation to discontinue semaglutide at least two months before a planned pregnancy, to allow for adequate washout given the drug’s approximately one-week half-life.

    For women with PCOS who are actively trying to conceive, this creates a specific clinical scenario that requires careful planning. Semaglutide can be used to improve metabolic parameters and potentially restore ovulatory function, then discontinued before conception is attempted. Effective contraception during treatment is required. The fertility benefit, if it exists, would need to manifest through improved baseline reproductive function that persists after drug discontinuation rather than through ongoing treatment during the conception window.

    This is an important conversation to have with a reproductive endocrinologist before starting semaglutide with the goal of improving fertility. The timing, the contraception plan, and the monitoring protocol all require individual clinical guidance. For a full discussion of the safety evidence around GLP-1 medications and pregnancy, including what the 2026 pharmacovigilance data shows, see our post: GLP-1 Medications and PCOS: What the 2026 Research Actually Shows About Fertility, Ovulation, and Pregnancy Safety.

    What Women With PCOS Can Do Right Now

    If you want to participate in a trial

    Search ClinicalTrials.gov using “semaglutide” and “polycystic ovary syndrome” for actively recruiting studies. The RESTORE trial (NCT05819853) at the University of Colorado is enrolling girls and women aged 12 to 35 with obesity and PCOS. Participation in clinical trials is not a last resort. It is how the field generates the evidence that eventually benefits all patients with the condition.

    If you are currently managing PCOS

    Semaglutide is not currently approved for PCOS, and prescribing it off-label for this indication without a diabetes or obesity co-diagnosis involves clinical judgments that should be made with a specialist, not based on online health content. Evidence-based options available today include metformin for insulin resistance, oral contraceptives or progestins for cycle regulation, spironolactone for androgen symptoms, and letrozole or clomiphene for ovulation induction in those trying to conceive. The 2023 International Evidence-Based PCOS Guideline from Monash University is a reliable reference for understanding the current standard of care.

    If you also have obesity or overweight

    If your BMI qualifies you for an obesity medication on its own merits (BMI 30 or above, or 27 or above with at least one weight-related comorbidity), semaglutide or another GLP-1 agonist may already be an appropriate treatment for your weight and metabolic health, and there is published evidence suggesting it also benefits PCOS features in this population. This is a conversation worth having with your gynecologist or endocrinologist, who can assess whether you meet criteria for approved obesity pharmacotherapy.

    We will be watching these trials closely.

    The RESTORE trial at the University of Colorado is the most clinically ambitious study of semaglutide in PCOS currently running, with results expected in 2028. For women with PCOS who have been managing symptoms with off-label therapies for years, the prospect of a drug that addresses the metabolic root of the condition rather than just managing individual symptoms is worth following carefully. The best resources for staying current on PCOS care include ACOG, the Androgen Excess and PCOS Society, and the international evidence-based PCOS guideline from Monash University.

    For more women’s health coverage on Health Evidence Digest, see our posts on new 2026 cervical cancer screening guidelines and the first FDA-approved non-hormonal endometriosis drug entering human trials.

    Sources

    RESTORE trial registration: Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome. NCT05819853. ClinicalTrials.gov.

    NCT06222437: Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy. Methodist Health System. ClinicalTrials.gov.

    NCT05646199: Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS). University of Hull. ClinicalTrials.gov.

    NCT06896981: Semaglutide in Women With Polycystic Ovary Syndrome and Obesity. BSMMU, Bangladesh. ClinicalTrials.gov.

    2024 meta-analysis (JDC): Morais BAA et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation. Journal of Diabetes and Its Complications. 2024;38(10):108834. doi:10.1016/j.jdiacomp.2024.108834

    2025 meta-analysis (Scientific Reports): Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women. Scientific Reports. May 2025. doi:10.1038/s41598-025-99622-4

    GLP-1 RAs in PCOS narrative review: Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS. Endocrine Connections. 2025;14(5). doi:10.1530/EC-24-0529

    2024 PCOS guideline meta-analysis: Goldberg et al. Anti-obesity pharmacological agents for PCOS: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obesity Reviews. 2024;25(5):e13704. doi:10.1111/obr.13704

    Combination semaglutide + metformin in PCOS: Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with PCOS. PMC12297736. pmc.ncbi.nlm.nih.gov. 2025.

    Patient resources: ACOG PCOS FAQ | Androgen Excess and PCOS Society | International PCOS Guideline | ClinicalTrials.gov

    Disclaimer: Health Evidence Digest provides general information about clinical research and health topics for educational purposes. This content is not a substitute for professional medical advice. Semaglutide is not FDA-approved for PCOS. Women with PCOS should speak with their gynecologist, reproductive endocrinologist, or healthcare provider about their individual treatment plan.